Phaseline

Targets › DDAH1

DDAH1 (N(G),N(G)-dimethylarginine dimethylaminohydrolase 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Jan 2027.

Hydrolyzes N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA) which act as inhibitors of NOS. Has therefore a role in the regulation of nitric oxide generation. (UniProt, O94760)

Open in Phaseline: the race on DDAH1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)Meropenem-Vaborbactam
Beta-lactam antibiotic combined with a beta-lactamase inhibitor; meropenem is a carbapenem
DDAH1Phase 2Acute PyelonephritisJan 2027

Conditions

Acute Pyelonephritis (1)

Modalities

small molecule (1)

Companies

Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.